Embryopathy due to valproic acid with severe malformations in the central nervous system;Embriopatía por ácido valproico con malformaciones graves del sistema nervioso central

Revista de Neurologia

Volumn 42, Issue 6, 2006, Pages 336-340

  Pardal Fernandez J M ^a   Carrascosa Romero, M C ^a   Rodriguez Vazquez M ^a   Marco Giner, J ^a   Martinez Gutierrez A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Brain malformation; Embryopathy; Fetal valproate syndrome; Gingival hyperplasia; Malformations; Valproate; Valproate embryopathy; Valproic acid

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT; TERATOGENIC AGENT;

ARTICLE; BRAIN ATROPHY; BRAIN MALFORMATION; CASE REPORT; CENTRAL NERVOUS SYSTEM MALFORMATION; DISEASE SEVERITY; EMBRYOPATHY; EPILEPSY; FACE DYSMORPHIA; GESTATION PERIOD; GINGIVA HYPERPLASIA; HISTORY OF MEDICINE; HUMAN; INFANT; MONOTHERAPY; PREMATURITY; ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; FEMALE; FETUS DISEASE; MALE; NEWBORN; PREGNANCY; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM; CRANIOFACIAL ABNORMALITIES; EPILEPSY; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS; VALPROIC ACID;

EID: 33749166374     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4206.2005349     Document Type: Article

References (43)

1. Arzimanoglou A, Guerrini R, Aicardi J. Aicardi's epilepsy in children. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 103-4.
2. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid [letter]. J Pediatr 1980; 97: 332-3.
3. Bailey CJ, Pool RW, Poskitt E, Harris F. Valproic acid and fetal abnormality. Br Med J 1983; 286: 190.
4. Nau H, Spielmann H. Embryotoxicity testing of valproic acid. Lancet 1983; 1: 763-4.
5. Tein I, MacGregor DL. Possible valproate teratogenicity. Arch Neurol 1985; 42: 291-3.
6. Robertson IG. Prescribing in pregnancy. Epilepsy in pregnancy. Clin Obstet Gynaecol 1986; 13: 365-84.
7. Gorlin RJ, Cohen Jr MM, Hennekam RCM. Syndromes of the head and neck. 4 ed. Oxford: Oxford University Press; 2001. p. 29-31.
8. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-8.
9. Jeavons PM. Sodium valproate and neural tube defects [letter]. Lancet 1982; 2: 1282-3.
10. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997-1004.
11. Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognizable phenotype? J Med Genet 1987; 24: 692-5.
12. Huot C, Gauthier M, Lebel M, Labrisseau A. Congenital malformations associated with maternal use of valproic acid. Can J Neurol Sci 1987; 14: 290-3.
13. Ardinger H, Atkin J, Blackston RD, Elsas L, Clarren SK, Livingston S, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171-85.
14. Chevallier B, Negre V, Bidat E, Lagardere B. Valproate induced fetopathy and somatic and psychomotor development. Arch Fr Pediatr 1989; 46: 627.
15. Cotariu D, Zaidman JL. Mini review: developmental toxicity of valproic acid. Life Sci 1991; 48: 1341-1350.
16. Clayton-Smith J, Donnai D. Fetal valproate syndrome. Syndrome of the month. J Med Genet 1995; 32: 724-7.
17. Espinasse M, Manouvrier S, Boute O, Farriaux JP. Embryofetopathy due to valproate: a pathology only little known. A propos of 4 cases. Arch Pediatr 1996; 3: 896-9.
18. Chabrolle JP, Poinsot J, Bruel H, Amussini P. Embryo-fetopathy due to valproate. Arch Pediatr 1997; 4: 288-9.
19. Crawford P. Epilepsy and pregnancy. Seizure 2002; 11 (Suppl A): S212-9.
20. Padmanabhan R, Hameed MS. Exencephaly and axial skeletal malformations induced by maternal administration of sodium valproate in the MF1 mouse. J Craniofac Genet Dev Biol 1994; 14: 192-205.
21. Elmazar MM, Vogel R, Spielmann H. Amniotic fluid cholinesterase of valproate-induced exencephaly in the mouse: an animal model for prenatal diagnosis of neural tube defects. Arch Toxicol 1988; 61: 501-3.
22. Padmanabhan R, Ahmed I. Sodium valproate augments spontaneous neural tube defects and axial skeletal malformations in TO mouse fetuses. Reprod Toxicol 1996; 10: 345-63.
23. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2: 937.
24. Lindhout D, Schmidt D. In utero exposure to valproate and neural tube defects. Lancet 1986; 1: 1392-3.
25. Oakeshott P, Hunt GM. Valproate and spina bifida. Br Med J 1989; 298: 1300-1.
26. Weinbaum PJ, Cassidy SB, Vintzileos AM, Campbell WA, Ciarleglio L, Nochimson DJ. Prenatal detection of a neural tube defect after fetal exposure to valproic acid. Obstet Gynecol 1986; 67 (Suppl 3): S31-3.
27. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42: 119-25.
28. Lindhout D, Omtzigt JGC, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42: 111-8.
29. Guibaud S, Simplot A, Boisson C, Pison H. Prenatal diagnosis of 4 cases of spina bifida in mothers treated with valproate. J Genet Hum 1987; 35: 231-5.
30. Gardner RJ, Savarirayan R, Dunne KB, McLellan JA, Coleman LT, Suthers GK. Microlissencephaly with cardiac, spinal and urogenital defects. Clin Dysmorphol 2001; 10: 203-8.
31. Gigantelli JW, Braddock SR, Johnson LN. Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embryopathy. Ophthal Plast Reconstr Surg 2000; 16: 52-4.
32. Malm H, Kajantie E, Kivirikko S, Kaariainen H, Peippo M, Somer M. Valproate embryopathy in three sets of siblings: further proof. of hereditary susceptibility. Neurology 2002; 59: 630-3.
33. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001; 98: 168-75.
34. Martínez-Frías ML. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 1990; 37: 277-82.
35. Ozkinay F, Cogulu O, Gunduz C, Yilmaz D, Kultursay N. Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. Mutat Res 2003; 534: 197-9.
36. Hockey A, Bower C, Goldblatt J, Knowles S. Fetal valproate embryopathy in twins: genetic modification of the response to a teratogen. Birth Defects Orig Artic Ser 1996; 30: 401-5.
37. Thisted E, Ebbesen F. Malformation, withdrawal manifestation, and hypoglycemia after exposure to valproate in utero. Arch Dis Child 1993; 37: 277-82.
38. Anderson HH, Rapley JW, Williams DR. Gingival overgrowth with valproic acid: a case report. ASDC J Dent Child 1997; 64 : 294-7.
39. Behari M. Gingival hyperplasia due to sodium valproate. J Neurol Neurosurg Psychiatry 1991; 54: 279-80.
40. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996; 23: 165-75.
41. Varnfield M, Botha J. Drug-induced gingival hyperplasia - a review. SADJ 2000; 55: 632-41.
42. Silverstein LH, Garnick JJ, Szikman M, Singh B. Medication-induced gingival enlargement: a clinical review. Gen Dent 1997; 45: 371-6.
43. Stoll C, Audeoud F, Gaugler C, Bernardin A, Messer J. Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero. Genetic Counseling 2003; 14: 289-98.